Fundamental Analysis of TONIX PHARMACEUTICALS HOLDIN(NASDAQ:TNXP) stock

Fundamental Rating

Overall TNXP gets a fundamental rating of 2 out of 10. We evaluated TNXP against 588 industry peers in the Biotechnology industry. TNXP has a bad profitability rating. Also its financial health evaluation is rather negative. TNXP is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

TNXP had negative earnings in the past year.

In the past year TNXP has reported a negative cash flow from operations.

In the past 5 years TNXP always reported negative net income.

TNXP had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

TNXP has a worse Return On Assets (-75.54%) than 68.32% of its industry peers.

Looking at the Return On Equity, with a value of -110.56%, TNXP is in line with its industry, outperforming 43.32% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-75.54%
ROE	-110.56%
ROIC	N/A

ROA(3y)-55.21%

ROA(5y)-86.34%

ROE(3y)-69.72%

ROE(5y)-119.89%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of TNXP (38.96%) is better than 79.45% of its industry peers.

TNXP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	38.96%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

TNXP does not have a ROIC to compare to the WACC, probably because it is not profitable.

TNXP has more shares outstanding than it did 1 year ago.

The number of shares outstanding for TNXP has been increased compared to 5 years ago.

TNXP has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -7.53, we must say that TNXP is in the distress zone and has some risk of bankruptcy.

TNXP's Altman-Z score of -7.53 is on the low side compared to the rest of the industry. TNXP is outperformed by 71.06% of its industry peers.

TNXP has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.

TNXP has a worse Debt to Equity ratio (0.06) than 62.33% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.06
Debt/FCF	N/A
Altman-Z	-7.53

ROIC/WACCN/A

WACC7.94%

2.3 Liquidity

A Current Ratio of 2.53 indicates that TNXP has no problem at all paying its short term obligations.

The Current ratio of TNXP (2.53) is worse than 72.77% of its industry peers.

TNXP has a Quick Ratio of 1.81. This is a normal value and indicates that TNXP is financially healthy and should not expect problems in meeting its short term obligations.

Looking at the Quick ratio, with a value of 1.81, TNXP is doing worse than 76.88% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.53
Quick Ratio	1.81

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 66.11% over the past year.

EPS 1Y (TTM)66.11%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q75.43%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, TNXP will show a very strong growth in Earnings Per Share. The EPS will grow by 26.39% on average per year.

TNXP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 195.86% yearly.

EPS Next Y62.81%

EPS Next 2Y36.24%

EPS Next 3Y26.39%

EPS Next 5YN/A

Revenue Next Year118.7%

Revenue Next 2Y78.76%

Revenue Next 3Y195.86%

Revenue Next 5YN/A

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TNXP. In the last year negative earnings were reported.

Also next year TNXP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

TNXP's earnings are expected to grow with 26.39% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y36.24%

EPS Next 3Y26.39%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

TNXP does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

TONIX PHARMACEUTICALS HOLDIN

NASDAQ:TNXP (4/24/2024, 7:00:01 PM)

Premarket: 0.16 0 (0%)

0.16

+0 (+2.04%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap13.52M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-75.54%
ROE	-110.56%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	38.96%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.05

Health

		Industry Rank	Sector Rank
Debt/Equity	0.06
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.53
Quick Ratio	1.81
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)66.11%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y62.81%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

TONIX PHARMACEUTICALS HOLDIN (TNXP)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens